Genmab Grants Stock Units and Warrants to Employees
Ticker: GNMSF · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-awards, employee-compensation, stock-options
Related Tickers: GMAB
TL;DR
Genmab just dropped RSUs and warrants to employees, standard retention play.
AI Summary
On November 20, 2025, Genmab A/S announced the grant of restricted stock units and warrants to employees. This filing is a Form 6-K report for the month of November 2025, and it will be incorporated by reference into Genmab's existing S-8 registration statements.
Why It Matters
This action indicates Genmab's strategy to incentivize and retain key employees through equity-based compensation, potentially impacting future performance and shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of employee stock grants, which is a common practice and does not present immediate material risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- November 20, 2025 (date) — Date of Company Announcement
- Form 6-K (document) — Filing Type
- Form S-8 (document) — Incorporated Registration Statements
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed by Genmab A/S to report a company announcement dated November 20, 2025, regarding the grant of restricted stock units and warrants to employees.
When was the company announcement regarding employee grants made?
The company announcement regarding the grant of restricted stock units and warrants to employees was made on November 20, 2025.
Which registration statements will this filing be incorporated into?
This filing will be incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What type of equity awards were granted to employees?
Genmab A/S granted restricted stock units and warrants to employees.
What is the principal executive office address of Genmab A/S?
The principal executive offices of Genmab A/S are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 225 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2025-11-20 15:22:39
Filing Documents
- gmab_20251120x6k.htm (6-K) — 13KB
- gmab_20251120xex99d1.htm (EX-99.1) — 20KB
- genmab_logo.jpg (GRAPHIC) — 56KB
- 0001434265-25-000102.txt ( ) — 108KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated November 20, 2025 Grant of Restricted Stock Units and Warrants to Employees in Genmab SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE NOVEMBER 20, 2025